Home CONTACT Neoplasma 2010 Neoplasma Vol.57, No.1, p.8-14, 2010

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.57, No.1, p.8-14, 2010

Title: Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma
Author: J. MINARIK, V. SCUDLA, J. BACOVSKY, M. ZEMANOVA, T. PIKA, M. ORDELTOVA, K. LANGOVA

Abstract: We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI ven after 40 months (median overall survival 25 vs 10months, p = 0.015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in all MM patients.

Keywords: myeloma – prognostication – proliferative index – biological therapy
Year: 2010, Volume: 57, Issue: 1 Page From: 8, Page To: 14
doi:10.4149/neo_2010_01_008
Price: 16.80 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.